Anonymous
07-22-2010, 02:10 PM
The company’s other promising investigational drug, a treatment for erectile dysfunction, a PDE-5 Inhibitor called avanafil — think a faster-acting Viagra - won’t have late-stage clinical trial results to present before 2012. If desperate, management could tap this compound as a source of cash, either through the sale of royalty rights or a collaborative deal (with up front monies)..... Why not just sell entire company to big pharma like Pfizer or Glaxo? http://industry.bnet.com/pharma/10009003/safety-concerns-may-sink-both-vivus-and-its-obesity-drug-qnexa/